Evidence map›Paper›PMID 39866193›Full record

ArticleJTO clinical and research reports2025

Afatinib and Necitumumab in

Nathaniel J Myall, Jennifer G Whisenant, Joel W Neal, Wade T Iams, Karen L Reckamp, Sally York, Lynne D Berry, Yu Shyr, Leora Horn, Heather A Wakelee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nathaniel J MyallDepartment of Medicine, Division of Oncology, Stanford University, Stanford, California.
Jennifer G WhisenantDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Joel W NealDepartment of Medicine, Division of Oncology, Stanford University, Stanford, California.
Wade T IamsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Karen L ReckampDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Sally YorkDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Lynne D BerryDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Yu ShyrDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Leora HornDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Heather A WakeleeDepartment of Medicine, Division of Oncology, Stanford University, Stanford, California.
Sukhmani K PaddaDepartment of Medicine, Division of Oncology, Stanford University, Stanford, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing Methods: This was a phase 1, dose-escalation, dose-expansion trial assessing the safety and efficacy of afatinib plus necitumumab. Patients had advanced or metastatic Results: A total of 22 patients with Conclusions: Afatinib plus necitumumab was safe but had limited activity in patients with

Indexed as

Dual EGFR inhibitionEGFR-mutatedLung cancerPhase I trial

Identifiers

PMID39866193
PMCPMC11759541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.